Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST (Details)

v3.24.1.1.u2
NON CONTROLLING INTEREST (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Net loss attributable to the non-controlling interest $ (687)   $ (934)
BioCorRx Pharmaceuticals, Inc [Member]      
Net loss $ (1,549) $ (1,447)  
Average Non-controlling interest percentage of profit/losses 24.20% 24.20%  
Net loss attributable to the non-controlling interest $ (375) $ (350)  
Joseph DeSanto MD [Member]      
Net loss $ (892) $ (1,668)  
Average Non-controlling interest percentage of profit/losses 35.00% 35.00%  
Net loss attributable to the non-controlling interest $ (312) $ (584)